Video

BenevolentAI · AI-Enabled Drug Discovery

Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long. This gives us the chance to solve the most intractable challenges of drug discovery - like excessive costs, high failure rates, low efficacy and the time it takes to get new drugs to market. But only if we unite human and artificial intelligence in the service of this goal. If we bring the most advanced technologies together with cutting edge science we can decipher complex disease biology, de-risk drug development, and discover more effective therapies for patients in need. We can build a healthier world in which no disease goes untreated. This is the future we are creating at BenevolentAI.

More Posts

You Might Also Like

News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022